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Chapter 1  
Introduction 
 
rugs misuse is a complex phenomenon that does not appear to have 
declined significantly in last decades, despite great efforts in terms of 
repression and therapeutic approaches. Interestingly, the Internet is now 
playing a key role in shaping how drugs are sold, changing the classic classification 
of new versus old drugs.  Indeed, a growing number of new drugs are now 
available on the internet drug market, including prescription drugs with 
psychoactive properties that are easier to obtain than illegal drugs. Among the 
prescription drugs whose recreational use is on the rise there is Benzydamine 
(BZY), a non-steroidal anti-inflammatory drug also abused as a club drug.  BZY 
abuse was first identified in Brazilian teenagers, and then spread to Poland and 
Romania, and other European countries (Opaleye et al, 2009; Mota et al, 2010; 
Babalan et al, 2013; Doksat et al, 2009; Settimi et al, 2012).  Today, BZY abuse 
has become the object of increasing concern in public health also in Italy. It is used 
because, when taken systemically at high doses, it produces euphoria, excitation, 
hallucinations, and delirium.  According to online forums, BZY causes a long-
lasting 'brain-flying' effect similar to LSD.  It seems that BZY is often taken in 
conjunction with tetrahydrocannabinol (THC) and alcohol to obtain an amplified 
effect.  The main goal of the present dissertation is to characterize the reinforcing 
properties of BZY using the intravenous drug self-administration in the rat and then 
to investigate the ability of BZY to induce neuroplastic changes in the cortico-
accumbens glutamatergic synapses, using slice electrophysiology. 
 
The question is frequently asked: Why does a man become a drug addict? The 
answer is that he usually does not intend to become an addict but he usually 
cannot choose to change his behavior. In Novel with Cocaine, a mysterious 
Russian novel first published in 1934 in a Parisian èmigrè publications, Mark Levi 
provides a disturbing account of a young man becoming addicted to cocaine; 
Vadim, the main character reflects: "Before I came in contact with cocaine I 
assumed that happiness was an entity, while in fact all human happiness consists 
D 
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of a clever fusion of two elements: (1) the physical feeling of happiness, and (2) the 
external event providing the psychic impetus for that feeling". This statement 
highlights the core element of drug addiction. A neutral non-reinforcing stimulus 
paired repeatedly with drugs use can acquire incentive salience and eventually, 
after a period of abstinence, it may trigger again drug craving and cause the 
relapse of the behavior (Stewart et al, 1984; Childress et al, 1988).  
To consider a patient dependent of drugs, the American Psychiatry Association 
requires he to meet at least three of the seven criteria: tolerance and physical 
dependence reflect physiological habituation to the effects of a drug, whereas other 
aspects as withdrawal, used larger amounts/longer, repeated attempts to 
quit/control use, much time spent using, activities given up to use and 
physical/psychological problems related to use, define the uncontrollable drug 
abuse. 
The human reward system is an extraordinary complex of billions of neurons that 
guide the behavior toward particular positive objectives, such as eating and 
procreation. Drug can integrate itself into these crucial mechanisms adapted for our 
survival, driving compulsive drug-seeking and drug-taking behavior, despite 
negative consequences.  Continued use of drugs induces adaptive changes in the 
central nervous system that lead to tolerance, physical dependence, sensitization, 
craving and relapse. Since long time, it has been tried to understand the 
neuropharmacological adaptation mediating the development and persistence of 
substance dependence. Early theories of addiction assumed that initial taking drug 
was driven by the positive reinforcing effects that it produces, but later is the 
recurrent drive for reward to determine the dependence disorder (Wise, 1980). This 
idea of positive reinforcement by drugs of abuse has been widely seen as a 
primary factor behind drug addiction (Gill et al, 1988). However, all drugs, after 
prolonged use produce the phenomenon of tolerance that lead to compensatory 
increases of dose and this can exacerbate the neurophysiological alterations in the 
brain. However, some drugs, such as psychostimulants, can produce an opposing 
response of tolerance, named sensitization that is an increase in the effects 
produce by drugs after a prolonged consume (Kalivas & Stewart, 1991; 
Anagnostaras & Robinson, 1996). Positive and negative reinforcement theories 
result suitable to explain the development and the maintenance of substances 
abuse, but they are not able to clarify more complex aspects of the phenomenon of 
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addiction, as the relapse phenomenon after a period of withdrawal. Currently, three 
theories are considered more prominent because have endeavored to clarify the 
complex aspects of the addiction disorder by considering all series of 
neuroadaptations that are consequence of prolonged abuse. We are talking about 
the hedonic allostasis theory of Koob and Le Moal, the incentive-sensitization 
theory of Robinson and Berridge and, finally, the ultimate theories relative to 
maladaptive learning processes and orbitofrontal cortex impairments in decision 
making processes. 
In their theory, koob and Le Moal suggested that repeated drugs use causes 
subsequent neuroadaptations that lead to the pathological shift of the drug user’s 
hedonic set point for the efficacy of reinforces and thus add motivational 
effectiveness to positive drug effects. Allostasis refers to the concept of physiology 
where an organism must vary all of the parameters of its internal milieu to maintain 
a state of equilibrium. Drugs produce disequilibrium in brain reward systems for 
which the individual allostatic processes, or the ability to achieve stability through 
change, can maintain an apparent stability at a new pathological ‘set point’. When 
the state of dysregulation reached is critical, therefore the organism is not more 
able to mobilize its own resources, allostasis reaches that point in which normal is 
considered illness. The state of dysregulation involving the reward system can 
produce loss of control over drug intake, compulsive use and drug addiction (Koob 
& Le Moal, 1997; Koob & Le Moal, 2001; Koob & Le Moal, 2005).  
Alternatively, Robinson and Berridge argued that drug-seeking and drug-taking 
behavior are not often motivated by the desire to obtain pleasure or the desire to 
relieve withdrawal. They suggest that addictive drugs regularly produce long-lasting 
neuroadaptations in the structures involved in the process of incentive motivation 
and reward, rendering these hypersensitive (‘sensitized’). Notably, they supposed 
that the brain structures sensitized by the prolonged use of drugs do not directly 
mediate the euphoric effects of substances (drugs liking), but instead they mediate 
a component of reward called incentive salience or drugs wanting (Berridge, Venier 
& Robinson, 1989; Berridge & Valenstein, 1991; Robinson & Berridge, 1993, 2000; 
Berridge & Robinson, 1995, 1998; Berridge 1996).   
More recently, multiple theories attempted to unveil the aspects of drug-induced 
neuroadaptations that may specifically explain the persistent nature of addictive 
behaviors: some authors sustain that the transition between the voluntary drug use 
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to habitual and compulsive consume is caused by the transition, at the neural level, 
from prefrontal cortical to striatal control (Wise, 2002; Everitt & Robbins, 2005; 
Volkom et al, 2006); others, support the hypothesis that the changes in the 
prefrontal cortical activity lead the impairment in behavioral control and decision-
making skills (Jentsch & Taylor, 1999; Franklin et al, 2000, 2002; Goldstein & 
Volkow, 2002) and others Authors consider the overlaps between limbic and 
cortical area involved in addiction and memory (Hyman & Malenka, 2001) so the 
behavioral disorders are considered the result in maladaptive associative learning 
(Di Chiara, 1999).  
 
Humans have used drugs for thousands of years: wine, narcotics, marijuana. But in 
the 19th century the active substances in drugs were extracted and the use of the 
so discovered drugs, cocaine, morphine, laudanum, became out of control. By the 
early 1900s there were an estimated 250˙000 addicts in the United States 
(Brecher, 1972). The problems of drugs addiction were recognized late, in fact the 
first national drug law in the United States was in the 1906. Throughout the years, 
the public’s perception of the dangers of specific substances changed. Today, the 
United States, estimates of the total overall costs of substance abuse exceed $600 
billion annually while in the European Union over 80 million adults are estimated to 
have used alcohol, nicotine, and illicit and prescription drug almost at least once in 
their life. 73.6 million adults have used cannabis, 141 million have used cocaine, 
11.4 million amphetamine and 10,6 million ecstasy. Of this, one-third of adults in 
Denmark, France and United Kingdom and less than one in 10 in Bulgaria, Greece, 
Cyprus, Hungary, Portugal, Romania and Turkey. In the most recent data, from 
2011, one in four 15- to 16- years old is estimated to have ever used an illicit drug, 
although prevalence levels vary considerably between countries (European Drug 
Report, trends and developments, 2014).  
During 2013, 81 new psychoactive substances were identified, 29 of which were 
synthetic cannabinoids, and other 30 compounds did not conform to the readily 
recognized chemical groups. There were also 13 new substituted phenethylamines 
reported, seven synthetic cathinones, a tryptamine and a piperazine (European 
Drug Report, trends and developments, 2014).  
In the last few years there has been an incredible change in the context of 
substances misuse. The revolution, and the consequently expansion, of the drugs 
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market could be 
mainly attributed to 
the new development 
in the distribution and 
communication of the 
recreational 
substances, probably 
due to the 
widespread of drug 
user communities 
and forums online in 
which people share 
their drug experience. 
Internet has played a 
major role in changing 
the trends of the global 
drugs market and today it continues to play a key role in shaping the phenomenon. 
The increased opportunities to share information online have made available to 
users, including young and vulnerable people, new pharmaceuticals and research 
chemicals. Although even now the main drugs used are opioid, psychostimulant 
and benzodiazepine, anticholinergic effects caused by painkillers, fever reducers 
and non-steroidal anti-inflammatory drugs (NSAID), such as delirium and 
hallucinations, support their use for recreational reasons.  
Non-medical use of the prescription drugs is an alarming public health problem, 
because a large amount of pharmaceuticals are taken nowadays not to treat the 
disease, but to improve some aspect of life and manage ordinary states, mood, 
sexual performing, body weight and cognitive ability, or, simply, for recreational 
reasons. This phenomenon is particularly severe among the student, because 
prescription drugs are widely available, off label prescribing, easy to acquire and 
are associated with fewer physical, legal and social risks, especially in comparison 
to illicit street drugs, (Quintero, 2009). 
The diffusion of always new substances, sometimes starting with experimentations 
in close settings, is now a global phenomenon that changes continuously and 
rapidly, so the available scientific literature is not able to gain sufficient technical 
Picture 1 Recreational use of prescription drugs is became a serious 
problem. National studies show that a teen is more likely to have abused a 
prescription drug than an illegal street drug. These because many people 
think prescription drugs are safe because they were prescribed by a doctor. 
[http://www.troymedia.com/2014/10/02/a-2-step-solution-to-reduce-the-
cost-of-prescription-drugs-for-canadians/]. 
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knowledge at the same pace. This is the reason why the European "Psychonaut 
web mapping project" was born, to 
monitor the web  looking for new 
drugs, to develop a technical 
database.  
In 2012, the project has led to 
identification of 412 new substances, 
classified in different categories: 
- Herbal: for example, Salvia 
Divinorum, a legal hallucinogenic plant.  
- Chemicals, such as mephedrone, that 
is a legal alternative to other stimulants, 
purchased online as ‘plant feeder’.  
- Combinations: Spice drugs and 
synthetic cannabinoid (as JWH-018) are an example. 
- Pharmaceutical: BZY, the object of this work, is one example. It is a non-steroidal 
anti-inflammatory drug (NSAID) abused recreationally for its euphoric and 
hallucinogenic effects at high doses (500-2000mg). 
 
 
 
 
  
Picture 2  Psychonaut Web Mapping Project Logo. 
The Psychonaut Web Mapping Project is a 2-year 
European Union funded project with the aim of 
developing a web scanning system to identify and 
categorize novel recreational drugs/psychoactive 
compounds, and new trends in drug use based on 
information available on the Internet. 
[http://www.psychonautproject.eu/]. 
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Chapter 2  
Epidemiology 
 
n recent years, abuse of BZY has been popular among teenagers and young 
adolescents, in Brazil, Romania and Poland but misuse cases are reported for 
Italy as well. 
Data on the adverse effects of BZY are scarce. In 1975 for the first time, Eggers 
have described few cases of intoxication of BZY in some children, (Eggers et al, 
1975). Recently, Gómez-López mentions a case of intoxication in a six-year-old girl 
who accidentally ingested 500 mg of BZY, suffering visual and tactile 
hallucinations: she was seeing and feeling flies, worms and birds travelling through 
her body, biting her and laying eggs. Hallucinations were progressively decreasing 
and disappeared in 3 hours after hospitalization, (Gómez-López et al,1990). In 
2006, Dogan et al, reported another case of BZY poisoning in an 11 years old girl 
who presented somnolence and visual hallucinations.  
Available scientific data about the recreational use of BZY psychoactive proprieties 
are pretty recent: a first description of the recreational use of this drug was 
mentioned in a survey with street youth, carried out in 1993. In the same year, a 
paper was published in which the Authors describe a case report of a  20-years-old 
man who, using between 400 and 1000 mg of BZY associated with alcohol, 
described visual alterations and hallucinations after 30 minutes, (Saldanha et al, 
1993). 
The use of BZY as a club drug is very popular, especially among teenagers, in 
Brazil, where it is mainly dispensed as tablets (50 mg) and a solution for oral use 
(3m mg/ml), sold with the commercial name ‘benflogin’ (a 20 ml bottle costs $3 and 
20 tablets cost $4). These drugs can be bought in Brazilian drug stores without the 
need for a medical prescription. Opaleye et al, (2009) published a cross sectional 
survey with children and adolescents, between 10 and 18 years old, in street 
situation, living in 27 Brazilian state capitals. Among the 2807 interviewed, 78 
reported having used BZY recreationally at least once in their lifetime; they 
described a dosage use ranged from 100 and 2000mg, in oral preparation. Some 
of them reported that they had associated this drug with another substance, 
I 
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commonly alcohol. All of them 
mentioned the substances by its trade 
name "Benflogin", which appears as 
the name of a weekly youth party in 
Rio de Janeiro that takes place in a 
privileged economic area, with the 
slogan “Shoo boredom now”. Another 
example is the use of the drug name 
as title of songs by certain Brazilian 
bands. Mota et al, in 2010 have 
published an exploratory essay to 
present information on the abuse of 
BZY, evidenced in scientific literature, 
press releases and on Internet, highlighting the need to strengthen pharmaco-
vigilance in Brazil. 
BZY preparations are sold over-the-counter in many countries and misuse reports 
are increasing. It is known that the phenomenon is expanding in Poland, Romania, 
Turkey, Spain and also Italy.  
In 2007, Anand et al. described a case involving a 22 years old polish man with a 
history of cannabinoid and alcohol abuse who was hospitalized for ingesting 500 
mg of BZY, after she found information about its hallucinogenic effects on the 
internet. 
In 2013, it was reported a first case in the Turkish literature about a 22 years old 
Turkish man hospitalized after taken a high dose of BZY (750 mg) with 500 ml of 
beer (Babalan et al, 2013). 
Normal dose of BZY may cause psychiatric side effects in patients with psychiatric 
disorders, and overdose may result in chronic psychosis. In 2009, it was reported a 
case of a 22 year old schizoaffective patient, who had been almost symptom-free 
for three years.  After a leg injury, she ingested 50 mg of BZY.  After two days, she 
had an episode of acute psychosis, with hallucinations, paranoia and dysphoria.  
The most likely explanation of this case is that BZY exacerbated the psychotic 
symptoms.  After 5 days of withdrawal from BZY, she returned symptom-free 
(Doksat et al, 2009).  
Picture 3 Trade name with which BZY Hydrochloride is 
sold in Brazil. Each box of Benflogin contains 20 pills, 50 
mg each. Benflogin is also the name used for weekly 
youth rave party in Rio de Janeiro. [http://anti-
inflamatorios.net/anti-inflamatorio-benflogin-beneficios-
efeitos-e-mais/]. 
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From 1977 to 2009, BZY 
was marketed in Italy by 
Angelini (with the 
commercial name of 
Tantum Rosa), as a 
pharmacy-supervised drug, 
that is, a non-prescription 
drug for which advertising 
to the public is prohibited.  
In 2009, Tantum Rosa was 
re-classified as over-the- 
counter drugs and 
advertising to the public was 
allowed. Unfortunately, one of the advertisements was illustrated by the silhouette 
of a woman with concentric circles on the abdomen, which may explain at least in 
part the increase in the number of erroneous oral ingestions of the drug (Settimi et 
al, 2012). 
In the last few years also in Italy some case of recreational use of BZY have been 
reported.  For example, the latest annual report on drug addiction to the Italian 
Parliament, includes a case report of a 34 year old girl, with a history of multiple 
substances abuse, hospitalized in Florence after oral ingestion, for recreational 
reasons, of 500 mg of Tantum Rosa. Another case report concerned a 22 year old 
man, with a history of cannabis and alcohol abuse, who, after reading on the 
internet about the psychoactive properties of BZY, decided to try it. (Relazione 
Serpelloni, 2012). 
  
Picture 4 Tantum Rosa is the Italian brand of BZY 
Hydrochloride. Each sachet contains 500 mg of the active 
principle. [http://comefare.com/come-usare-il-tantum-rosa/]. 
 
 
13 
 
Chapter 3 
Pharmacology 
 
enzydamine [3-(1-Benzyl- 
1H-indazol-3-yloxy)-N,N-
dimethylpropan-1-mine], 
available as the hydrochloride form, is 
a non-steroidal anti-inflammatory drug 
(NSAID) synthesized in Italy by the 
Angelini research Laboratories in 
1964 and marketed in 1966. it has 
analgesic, anti-inflammatory, 
antipyretic and antimicrobial 
properties, providing rapid and 
extended pain relief. BZY preparations 
are marketed throughout the world for 
the symptomatic treatment of oropharyngeal and gynecological conditions, as a 
mouthwash, aerosol, dermal cream, vaginal douche, pill, and eye drop. Used in 
odontostomatology to treat gingivitis, stomatitis, glossitis, aphthous ulcers, dental 
surgery and oral ulceration due to radiation therapy. In otorhinolaryngology, BZY is 
used for pharyngitis, tonsillitis, post-tonsillectomy, radiation or intubation mucositis. 
(Gomez-Lopez et al. 1999).  
BZY is available as mouthwash (Tantum Verde) throughout Europe. In the UK it is 
sold under the trade name Difflam, as Difflam spray, Difflam oral rinse and Difflam 
cream (Doksat, 2009).  
 
 
Picture 6 List of Brands with which BZY hydrochloride is sold in some Countries. [BZY report; Psychonaut 
Web Mapping Project]. 
B 
Picture 5 Molecular 2D structure of BZY, a benzyl-
indazole with analgesic, antipyretic and anti-
inflammatory effects. [Benzydamine report; 
Psychonaut Web Mapping Project]. 
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In Australia it is 
available as 
Difflam-C-
Alcohol & color 
free solution, 
Difflam 3% Gel, 
Difflam Extra 
strength Gel 5%, 
Difflam-C-
Solution, Difflam 
Solution 
(including 
Difflam throat 
spray), Difflam 
Cream and 
Difflam 
Lozenges 
(Doksat, 2009). 
BZY is also sold 
in Eastern 
Europe, without 
prescription named 
Tantum Rosa – as vaginal antiseptic and anti-inflammatory preparation, containing 
0.14 g of BZY hydrochloride to be reconstituted with clean water to a 0.1% (1 
mg/ml) solution for vaginal enema/instillation.  
In Brazil it is sold, by prescription, under the name ‘benflogin’, while in Pakistan 
under the name Tantum Capsule (50 mg). In Egypt, BZY is available in a cream 
and gel named Tantum Fort, while in Canada it is sold as a mouthwash named 
Novo-Benzydamine. In Turkey it is cheap and sold over-the-counter in all 
pharmacies as Tantum, Tanflex and Benzidan. 
 
 
 
 
Picture 7 Proprietary and multi-ingredient names of Benzydamine preparations 
and the countries where they are marketed. [Benzydamine report; Psychonaut 
Web Mapping Project]. 
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3.1 Chemistry 
 
BZY is fluorescent (excitation 306 nm; emission 362 nm) and is detected 
fluorometrically in HPLC assays. This absorbance and fluorescence in the 
ultraviolet region may be associated with a possible pharmacological effect. It has 
been suggested that BZY and related compounds may reduce the formation of 
cataract due to absorbance in the UV region or by a molecular interaction with lens 
protein, reducing the UV damage (Jez JM et al, 1996).  
 
3.2 Pharmacodynamics 
 
BZY, unlike other non-steroidal anti-inflammatory drugs (NSAID), is not ulcerogenic 
and does not inhibit cyclooxygenase or lipoxygenase. Moreover it has different 
pharmacological activities consider those of other NSAID. In fact, it is a weak base, 
unlike aspirin-like non-steroidal anti-inflammatory drugs, (which are acids or are 
metabolized to acids) and is a weak inhibitor of the synthesis of prostaglandins. 
Nevertheless, BZY has several properties which may contribute to its anti-
inflammatory activities, because it reduces locally induced inflammation, edema 
and granuloma formation in animals and demonstrates antipyretic and anti-
exudative activities. (White SK, 1988). 
BZY has affinity for membrane, with membrane-stabilizing properties and has local 
anesthetic effects. It inhibits phagocyte degranulation and aggregation and 
production of reactive oxygen species by phagocytes and leukocyte adhesion to 
vascular endothelium. Moreover, it has also antithrombotic properties, reduces 
platelet activation factor (PAF) and inhibits tumour necrosis factor (TNF) properties 
and the synthesis of the inflammatory cytokine, (Anand et al, 2007). 
Finally, BZY possesses also non-specific antibacterial activity at the concentrations 
used in mouthwashes, in fact, it exhibits activity against bacterial strains resistant 
to broad-spectrum antibiotics, such as ampicillin, chloramphenicol and tetracycline, 
at a concentration of 3 mmol/l. This property may prevent the development of 
secondary bacterial infections following viral-induced pharyngitis. (Quane et al, 
1998).  
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When taken at high doses, BZY mimics the 
effects of the psychedelic compound, LSD, 
causing visual alterations and 
hallucinations. The exact mechanism of 
action for the hallucinations induced is 
unknown but all of these substances with 
psychedelic properties, including BZY, are 
structurally similar to the neurotransmitter 
Serotonin, because of the presence of the 
Indole compound (Doksat et al, 2009). Indole 
is an aromatic heterocyclic compound, 
consisting of a Benzene ring with six atoms of Carbon and a five-membered 
nitrogen-containing Pyrrole ring.  Indole compound alone has not psychotropic 
effects, but it represents the central nucleus of different psychedelic substances, 
such as LSD, Psilocybin and Mescaline.  
 
Picture 9 Molecules contain the indole compound. a. BZY; b. Serotonine; c. LSD; d. Dimethiltriptamine. [Ref. 
Wikipedia]. 
 
Picture 8 Indole compound. It has a bicyclic 
structure, consisting of a six-membered 
benzene ring fused to a five-membered 
nitrogen-containing pyrrole ring. Molecular 
formula C8H7N; Molecular massa 117.15 g/mol. 
[Ref. wikipedia]. 
a b 
c 
d 
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Serotonin is considered an essential neurotransmitter involved in many basic brain 
functions, linked to mood, sleep, appetite, regulation of the involuntary smooth 
muscles but also depression and anxiety. Serotonin is thought to exert its relaxing 
effects on brain by making neurons less likely to fire. It seems that psychedelics 
exert their effects by an agonist or partial agonist action at serotonin 5HT2A 
receptors. Early hypothesis support the involvement of 5HT2A receptors in the 
principal hallucinogenic action of some drugs was suggested by Glennon et al 
(1983c) based on the results of drug discrimination studies using rats, in which 
5HT2A antagonists ketanserin and pirenperone blocked the discriminative stimulus 
effects of hallucinogens, including LSD. Moreover, it has been demonstrated that 
ketanserin abolishes virtually all of the psilocybin-induced subjective effects in 
humans (Vollemweider FX et al, 1998).  
5HT2A is a trans-membrane G protein-coupled receptor (GPCRs) member of the 
5HT2 receptor sub-family of serotonin, linked to the inositol phosphate (IP) signal 
transduction (Wainscott et al, 1993)., When activated, 5HT2A stimulates 
phospholipase C (PLC), which heads a downstream activation of protein kinase C 
(PKC) as well as an increased release of Ca2+ from intracellular stores. Using 
quantitative auto-radiographic analysis, it has been demonstrated  a widespread 
distribution of 5HT2A receptors in several regions in the brain, including Olfactory 
Bulb, Nucleus Accumbens, Olfactory Tubercle and the Tractus Solitarius, although 
a large amount are located in the cerebral cortex (Lopez-Gimenez et al, 1997), as 
demonstrates the ubiquitous effects of hallucinogens on such complex processes, 
as cognition, perception and mood, all superior functions that involve the cerebral 
cortex. Moreover, various studies have demonstrated that activation of cortical 
5HT2A receptors, using hallucinogenic drugs or serotonin, heads to a strong 
increase in glutamate-dependent activity in pyramidal neurons of the prefrontal 
cortex (PFC) (Aghajanian et al, 1999; Puig et al, 2003; Beique et al, 2007). At the 
beginning, nevertheless, it was thought that this increase in glutamatergic synaptic 
activity was produce by a stimulation of glutamatergic thalamo-cortical afferents to 
the PFC, which express 5HT2A receptors pre-synaptically. However, more recent 
studies have suggested the direct involvement of post-synaptic 5HT2A receptors 
on a subpopulation of pyramidal cells in the layer V of the PFC.  
However, the biggest serotoninergic nucleus in the brain is the dorsal raphe 
nucleus, located in the midbrain. Notably, the dorsal raphe nucleus exerts 
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downstream effects on serotonergic and dopaminergic activity through descending 
projections that contact the ventral tegmental area (VTA), causing indirectly the 
activation of 5-HT2A receptors in the medial PFC (mPFC), with consequent 
increase in the firing rate of 5-HT neurons in the dorsal raphe and dopamine 
neurons in the VTA (Celada et al, 2001; Vazquez-Borsetti et al, 2009).  
A recent study reported that the 5HT2C receptor may be involved in the 
hallucinogenic process (Sanders-Bush and Breeding, 1991). The 5HT2A and 5HT2C 
receptors have similar molecular and pharmacological properties and have similar 
affinities for LSD (Teitler et al, 1987).   
 
3.3 Pharmacokinetic and bioavailability 
 
Commercially, BZY is available in different formulations (chapter 2) because it can 
be used orally or topically.  Following topical application on skin or mucosa, the 
absorption is usually less than 10% of total dose and the bioavailability is of 5% 
with a peak of 0.05 µmol/l after 3 hours. Nevertheless cutaneous application 
produces slow and prolonged penetration through the tissue: after the application 
of 100 mg of BZY to human skin, it is reveal in plasma and urine (Andersson et al, 
1974). 
Differently, following oral administration of 50 mg of BZY hydrochloride in an 
aqueous solution, gastrointestinal absorption is very fast and almost complete; 
peak plasma concentrations of 1.5 µmol/l are obtained after 1 hour and half. 
Approximately 64% of the dose is absorbed in 1h, and complete absorption occurs 
in 4-6 hours. The high oral absorption is probably related to the high lipid solubility 
and relatively low systemic clearance (160 ml min-1) which is about one tenth of 
liver blood flow, while it has an high volume of distribution (110L). In the blood 
system benzydamine is relatively less likely to bind proteins than other non-steroid 
anti-inflammatory agents (15-20%), so after oral doses it reaches a very high 
bioavailability (87%) and the plasmatic half-life is 7-8 h. 55% of total dose is 
excreted unchanged in the urine while the 45% is metabolized by the liver (for 
oxidation, dealkylation and coniugation), in inactive metabolites, excreted both in 
the urine and the faeces. One metabolite, BZY N-oxide, is present in the plasma at 
a peak concentration of approximately 0.6 µmol/l (Quane et al, 1998). 
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Picture 10 Metabolites of BZY. The formation of the N-oxide hydroxy metabolite 
requires two metabolic processes, (Quane et al, 1998). 
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3.4 Pharmacological and toxicological effects 
 
Acute poisoning with NSAID is associated with a variety of features: hallucinations, 
headache, nystagmus, diplopia, tinnitus, dizziness, blurred vision, seizure, 
dyskinesia, lethargy, loss of consciousness and coma. Hypotension and 
tachycardia are sometimes present. Vomiting is an important early sign NSAIDs 
overdose, and abdominal pain, nausea and intestinal bleeding. Granulocytosis, 
pancytopenia and coagulopathy may also occur.  
Recreational use is associated with different desired psychoactive effects: feeling 
of well-being, euphoria, excitation, disinhibition, talkativeness, feeling of weight 
loss; and at high doses, delirium and hallucinations (Balaban et al, 2013).  
 
The use of hallucinogenic drugs, also BZY, can induce a variety of powerful 
perceptual symptoms including kaleidoscopic images, altered shapes and colors 
and trails of moving objects (Dubois & VanRullen, 2011). Hallucinogenic drugs are 
considered relatively harmless to self and others compared to heroin and cocaine 
(Nutt et al, 2010), however they may impair mental functions, causing psychosis 
(Geyer & Vollenweider, 2008) and sometimes the ‘hallucinogen persisting 
perception disorder’ (HPPD), a syndrome colloquially indicated as ‘flashbacks’ 
(Abraham and Aldridge, 1993; APA DSM-V 2013). An individual’s perception can 
be severely altered by certain drugs, but effects slowly wear off as a result of its 
metabolism and excretion. In some individual, however, may undergo prolonged 
changes in their normal perception that persist for weeks to indefinite time after 
exposure (Abraham & Duffy, 1996; Lerner et al, 2000). HPPD patients have visual 
hallucinations in the form of trailing colours, the sensation that something is moving 
in the peripheral field of vision although there is nothing there, trailing phenomena - 
moving objects leave trails or after-images, positive after-images (an image that 
retains the original color), color flashes when lighting is low, colours of increased 
intensity, haloes surrounding objects, macropsia and micropsia (objects appear 
respectively larger or smaller than normal), (Erowid org, 2009; Halpern & Pope, 
2003). A type of neuron that is possibly involved in the etiology of HPPD is the 
inhibitory cortical interneuron, which expresses 5-HT2A receptors and releases 
GABA upon activation (Abraham & Aldridge, 1993). Inhibitory mechanisms are 
important to suppress neuronal responses when the stimulus is no longer present 
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and a lack of lateral inhibition may decrease the ability to process edges and 
thereby result in the perception of halos. 
 
3.5 Recreational use 
 
BZY hydrochloride, an easily accessible and inexpensive NSAID, taken orally at 
high doses, 500 mg to 3000 mg, is a central nervous system stimulant, rather likely 
to be abused. It is considered by the users to be a potent substance that gives a 
bigger sense of reality, in an unpredictable way. The effects are similar to those of 
LSD, because both are hallucinogenic and are preferred by users to be taken at 
parties, with friends or a group of people. Frequently, BZY is taken in combinations 
with other drugs, cannabis, alcohol, Dextromethorphan and amphetamine.  BZY is 
taken principally orally, in the form of tablets or dissolving the content of the 
sachets (TANTUM® Rosa) in sugar water o in juices for cover the salty taste. Only 
in rare cases, the content of the sachets is snorted. 
A person who takes BZY at high doses may experience several effects, as feeling 
of well-being, euphoria hallucinate, paranoia, dry mouth and sometimes 
convulsions. The trip can last up to 8 hours, after that the user becomes tired and 
quiet, but sleeping is almost impossible.  
A psychedelic experience regards the perception of aspects of mind and 
consciousness previously unknown, the creative exuberance of the mind liberated 
from its ordinary bondage. Psychedelic states represent an array of experiences, 
changes of perception, synesthesia, altered states of awareness, mystical states, 
and occasionally states resembling psychosis, elicited by sensory deprivation as 
well as by psychedelic substances.  
 
Plants containing hallucinogens substances have been used by tribal societies for 
medical and religious practices for thousands of years.  ‘Psychedelic’ is an English 
term derived from the Greek words ‘Soul’ (Psyche) and ‘manifest’ (Delos). Jaffe 
(1990) provided a definition for hallucinogens: “the feature that distinguishes the 
psychedelic agents from other classes of drugs is their capacity to reliably induce 
states of altered perception thought, and feeling that are not experienced otherwise 
except in dreams or at times of religious exaltation”.  
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The use of psychedelic began in 1950s after the strong distribution of classical 
hallucinogen lysergic acid diethylamide (LSD), discovered by Albert Hoffmann. 
Research into experimental, chemotherapeutic and psychotherapeutic use of 
psychedelic drugs was conducted over the next 10-15 years, all over the world. 
Psychedelics use was widely diffused in the past between those people who want 
to achieve altered state of consciousness and investigate the psyche, because 
these substances facilitate the psychoanalytic processes. In more recent years 
these were particularly useful for patients with problems what were difficult to treat, 
including alcoholics. In fact, in the 1965 there were more than 1000 published 
clinical studies supporting therapeutic effects in over 40000 subjects. LSD, 
psilocybin and sporadically ketamine have been reported to have therapeutic 
effects in patients with anxiety, alcohol addiction and other brain disease 
(Vollenweider & Kometer, 2010). 
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Chapter 4 
The reward system 
 
lds and Milner experiments, in 1954, provided some of the first key 
evidence for the existence of several structures in the brain that, if 
stimulated electrically, can produce a reinforcing effect; Authors reported 
that experimental animals were able to develop an operant behavior that had 
electrical stimulation of these areas as a scheduled consequence. These results 
have permitted to hypothesized that also drugs of abuse may produce reinforcing 
effects performing their action in the same regions, binding the receptors for the 
endogenous chemical messenger: For example, opioids act at opiate receptors, 
nicotine at nicotinic acetylcholine receptors and phencyclidine at NMDA receptors, 
and so on. Although drugs of abuse often produce different behavioral effects and 
have different pharmacological profiles, all share the ability to enhance the 
extracellular dopamine levels in the nucleus accumbens (Wise, 1996).  
Although they account for less than 1% of the total neuronal population (Arias-
Carrion et al, 2007), dopaminergic neurons have a profound effect in the adult 
brain functions. Principally, their activity is involved in the processes of learning and 
memory (Kandel, 2001) and in reward-related behavior underlying drug addiction 
(Pessiglione et al, 2006). Dopaminergic cells interconnect the areas that shape the 
complex system which originates in the substantia nigra pars compacta (SNpc), 
ventral tegmental area (VTA) and hypothalamus (Arias-Carrion et al, 2007; 
Bjorklund et al, 2007). Considering the related functions, dopaminergic system was 
originally considered as four major pathways: mesocortical, mesolimbic, 
nigrostriatal and tuberoinfundibular (Arias-Carrion et al, 2010), (Picture 11). 
The nigro-striatal pathway originates in the substantia nigra pars compacta and 
extends its fibers into the caudate-putamen nucleus, forms with cortex, thalamus 
and basal-ganglia, a complex system involved in the control of movement (Smith et 
al, 2008). 
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The tubero-infundibolar pathway begins in the arcuate nucleus of the medio-basal 
hypothalamus (the tubero region) to the median eminence (the infundibolar region). 
This pathway is involved in the regulation of the secretion of prolactine from the 
anterior pituitary gland (Porter et al, 1990; Reymond et al, 1985).   
The mesolimbic and mesocortical pathways play a pivotal role in drug reward and 
pathological neuroadaptations in this circuitry are thought to be implicated in the 
development of drug addiction (Koob et al, 1992; Robinson & Berridge 1993, 2000; 
Heimer, 2003; Everitt & Robbins, 2005; Nestler, 2005; Zhang et al, 2006; 
Feltenstein & See, 2008).  
The mesolimbic dopaminergic system includes the projections from the ventral 
tegmental area to the nucleus accumbens, as well as the olfactory tubercle 
innervating the septum, amygdala and hippocampus (Oades & Halliday, 1987). On 
the other hand, the mesocortical dopaminergic system includes ventral tegmental 
area that projects to the prefrontal, cingulate and perirhinal cortex (Bannon & Roth, 
1983). Because of the overlap between these two pathways, they are often 
considered a unique system, sometimes called mesocorticolimbic dopamine 
system (Bjorklund & Dunnett, 2007a), (Picture 12).  
Mesocorticolimbic circuit is a complex involved in the attribution of incentive value 
to biologically relevant stimuli, resulting in the production of adaptive behaviors, 
Picture 11 Dopaminergic pathways, neural pathways in the brain that trasmit the neurotrasmitter dopamine 
from one regione of the brain to another. In the image are shown the four major dopaminergic pathways: 
mesolimbic pathway, from ventral tegmental area to the limbic system via the nucleus accumbens; 
mesocortical pathway, from the ventral tegmental area to the frontal cortex; nigrostriatal pathway from the 
substantia nigra to the striatum; tuberoinfundibolar pathway, from the hypothalamus to the pituitary gland. 
[http://www.medscape.org/viewarticle/585155] 
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crucial for survival (Kelley & Berridge, 2002). Growing experimental evidences 
suggest that drugs of abuse exert their dominant control over behavior launching 
this circuitry and altering its functions. Notably, both acute and repeated drugs 
exposure, directly or indirectly, activates dopamine release in the nucleus 
accumbens and cause long-lasting alterations in the structures of the reward 
system, particularly ventral tegmental area and nucleus Accumbens (Berke 
&Hyman, 2000; Henry et al, 1989; Henry & White, 1995; Hu et al, 2002; Nestler, 
2004, 2005; Pierce & Kalivas, 1997).  The Nucleus Accumbens, that is, the ventral 
part of the striatum, plays a key role as interface between the limbic system to 
basal ganglia and extrapyramidal motor system, but also involved in the generation 
of motivated behaviors and in spatial memory and adaptive processes (Berridge, 
2007; Ikemoto, 2007; Nicola, 2007). Notably, it facilitates reward-seeking because 
act as an interface by integrating dopaminergic reinforcement signals with 
glutamate-encoded environmental stimuli (Brown et al, 2011; Day et al, 2007; 
Flagel et al, 2011; Philips et al, 2003; Stuber et al, 2008; Volkow et al, 2003, 
Schacter et al, 1989; Pennartz et al, 1994). 
Nucleus accumbens is generally considered as two distinct sub-regions named 
shell and core, respectively in the ventro- and dorso- medial position and with 
different anatomical connectivity. Cells in the core, involved in motor functions, 
project strongly to the zona compacta of the substantia nigra, while shell, involved 
in emotions as a transition area of the extended amygdala, projects strongly to the 
Picture 12 Mesolimbic and mesocortical pathways of dopamine. These two highly conserved systems play a 
critical role in the assignment of motivational value to biologically relevant stimuli, resulting in the production of 
the adaptive behaviors. Because of the overlap between these two systems, they are often considered the 
unique mesocorticolimbic system (Bjorklund and Dunnett, 2007a). [anatomie.lf3.cuni.cz]. 
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ventral tegmental area (Alheid & Heimer, 1988; Heimer et al, 1991). Considering 
the cytochemical aspects of the nucleus accumbens, a different subdivision in 
other two different compartments is possible: the larger one named matrix receives 
afferents from the primary sensory and motor areas of the cerebral cortex and from 
a subset of dopaminergic neurons in the substantia nigra pars compacta; 
additional, it sends projections to the substantia nigra pars reticulata. Within the 
matrix, somatostatin-containing neuronal processes have been found, as well as 
neurons positive for choline acetyl-transferase, acetylcholinesterase, muscarinic 
cholinergic receptors. Binding sites for µ opioid receptors are instead less present.  
The other compartment, named striosome or patches, is much smaller, accounting 
for only 10% of the neostriatal volume. The striosome receives afferents from a 
restricted and less easily characterized area in the cortex and from dopaminergic 
neurons in the substantia nigra, while projecting to the substantia nigra pars 
compacta. The striosome is relatively poor in acetylcholinesterase, choline 
acetyltransferase and muscarininc cholinergic receptors and contains a very high 
concentration of µ opioid receptors (Kawaguchi et al, 1989). 
The principal population of neurons in the nucleus Accumbens, GABAergic 
Medium Spiny Neurons (MSN), account for the 95% of the cells total, ) while the 
remaining 5% consist of a very heterogeneous population of interneurons, 
including fast spiking interneurons (FS), low spiking interneurons (LS), tonically 
active cholinergic neurons (TAN) and GABAergic interneurons (Tapper & Bolan, 
2004). Medium spiny neurons make synapses with other MSN and cholinergic 
interneurons but not with fast spiking (FS) interneurons. In turn, all interneurons 
make synapses principally with MSN (Chuhma et al, 2011).  
Nucleus Accumbens, compared to the dorsal striatum, is less ordered (Sesack & 
Grace, 2010). However, core has an organization similar to that of the dorsal 
striatum, while shell has an organization which is an hybrid between striatum and 
amygdala.  
Although, traditionally, dopamine has received most attentions as the key player in 
drug addiction, another considerable body of literature provides evidences for the 
role of glutamate in the adaptive processes emerging after a prolonged use of 
drugs: in fact, the activation of the prefrontal cortex is commonly observed in brain 
imaging studies, in human addicts that are exposed to drug associated stimuli 
(Goldstein & Volkow, 2002). 
 
27 
 
Glutamate is the most important excitatory neurotransmitter at the synapses 
between prefrontal cortex, ventral hippocampus, basolateral amygdala and the 
midline thalamus to the medium spiny neurons of the nucleus accumbens (Wolf 
1998; Kalivas & O’Brien, 2008; Britt & Bonci, 2013; Horne et al, 1990).  
Here, we focus on the prefrontal cortex (PFC), a brain area involved in attention, 
decision making, cognitive flexibility, learning and responses to environmental 
stimuli (Groenewegen & Uyling, 2000; Miller 2000; Robbins, 2000a; Miller & 
Cohen, 2001; Dalley et al, 2004). Prefrontal cortex, through efferent projections to 
the nucleus accumbens, can assimilate both sensory and limbic information to 
support goal-directed behavior (Robbins & Everitt 1996). it sends glutamatergic 
projections to the ventral tegmental area, septal areas and basal forebrain (Geisler 
et al, 2007; Vertes, 2004) while, in turn, VTA sends dopamine outputs to nucleus 
accumbens, hippocampus and amygdala (Sesack & Pickel, 1990; Gasbarri et al, 
1994; Hasue & Shammah-Lagnado, 2002) and others sends cholinergic 
projections to hippocampus and amygdala (Gaykem et al, 1990; Carlsen et al, 
1985). In this way, the prefrontal cortex can exert a modulation on the activity of the 
nucleus accumbens, hippocampus and amygdala, both directly through the 
glutamatergic efferent projections and indirectly through the activation/inhibition of 
dopamine and cholinergic inputs (Robbins 2000b; Gabbott et al, 2005). 
The rodent prefrontal cortex is divided in anterior cingulate cortex (dorsomedial 
portion), prelimbic and infralimbic cortex (ventromedial portion) and orbitofrontal 
cortex (Franklin & Chudasama, 2012), and all receive the most part of 
dopaminergic efferents that leave ventral tegmental area dopamine neurons 
(Tzschentke 2001; Tritsch & Sabatini, 2012). The 80% of the total prefrontal cortex 
population is represented by excitatory glutamatergic pyramidal projection neurons 
and GABAergic inhibitory interneurons (Homayoun & Moghaddam, 2007; Card et 
al, 1999; Beaulieu, 1993). Like other cortical areas, prefrontal cortex is subdivided 
in six layers with characteristic type of neurons and connections (Mountcastle, 
1997; Douglas & Martin, 2004). In particular, the most prominent type of cortical 
neurons are pyramidal neurons located in layers V and VI and receive projections 
from ventral tegmental area while projecting to layers II and III and to subcortical 
areas, including the ventral tegmental area and nucleus accumbens (Carr & 
Sesack, 2000; Douglas & Martin, 2004; Gabbott et al, 2005). Dopaminergic and 
glutamatergic synapses shape the so-called ‘triads’ that are thought to be the 
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structural basis for the direct dopamine modulation of glutamatergic transmission 
(Law-Tho et al, 1994).  
The brain circuitry involved in drug addiction is complex and prolonged drugs use 
can underlie deep neural adaptations as consequences of in vivo exposure to 
drugs of abuse (Robinson & Berridge, 1993; Kalivas, 1995; Wolf, 1998; Hyman 
&Malenka, 2001; Nestler, 2001; Carlezon & Nestler, 2002; Everitt & Wolf, 2002; 
Hyman et al, 2006). Although neuroadaptations directly related to dopaminergic 
activation appear crucial for the development of addiction, once it is developed, the 
impaired ability of addicts to regulate drug seeking and drug-taking behaviors is 
thought to be dependent of long-lasting neuroadaptations at the prefrontal 
glutamatergic input to the nucleus accumbens (Luscher & Malenka, 2011; Nestler 
2001; Kalivas & Volkow, 2011; Kalivas & O’Brien, 2008; Kalivas et al, 2004; Self et 
al, 2004). Clinical investigations revealed that the basal activity in the prefrontal 
cortex is reduced in addicts during withdrawal, but can increase rapidly following 
presentations of drug-associated cues. Biologically, the presentation of stimuli 
associated with positive reinforces strongly activate the PFC-accumbens pathway 
in normal subjects, but in addicts the increase is brusque (Garavan et al, 2000). 
Imaging studies have shown the association between the impairments in prefrontal 
cortex and reduction of dopaminergic function suggesting the hypothesis of the 
involvement of dopamine in the drug-induced neuroadaptations in the prefrontal 
cortex. Similarly, behavioral studies have demonstrated that blocking 
AMPA/kainate glutamate receptors in the nucleus accumbens prevents the 
reinstatement of drug seeking (Cornish & Kalivas, 2000; Di Ciano & Everitt, 2001; 
Park et al, 2002); moreover, microdialysis estimates of extracellular glutamate 
reveal an increased release of glutamate in the projections from the prelimbic 
cortex to the core compartment of the nucleus accumbens during drug seeking 
(McFarland et al, 2004). Finally, it was demonstrated that repeated in vivo 
psychostimulant exposure increases the number of dendritic spines (Robinson and 
Kolb, 2004), cell surface expression of AMPARs (Boudreau & Wolf, 2005) and the 
behavioral response to AMPA infusion in the nucleus accumbens (Pierce et al, 
1996; Cornish & Kalivas, 2000; Suto et al, 2004).  
The adaptations known in the nucleus accumbens, as consequences of prolonged 
use of drugs, can be modelled using long-term potentiation (LTP) and long-term 
depression (LTD) paradigms. It is now accepted that either LTP or LTD are basic 
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properties of most excitatory and inhibitory synapses throughout the central 
nervous system and can be used experimentally for studying multiple brain 
functions (Malenka & Bear, 2004). Notably, using electrophysiological methods in 
brain slices, different forms of LTP and LTD in the brain have been identified. The 
two best-understood forms of long term potentiation in the mammalian brain are 
the NMDAR-dependent LTP and the presynaptic LTP. The former involves both 
presynaptic and postsynaptic neurons because when glutamate is released the 
postsynaptic neuron must be depolarized. Therefore, glutamate binds NMDA 
receptors on the postsynaptic membrane and rises the calcium influx which 
activates intracellular signaling cascades responsible for the changing in synaptic 
efficacy (Bliss & Lomo, 1973; Malenka & Bear, 2004; Malenka & Nicoll, 1999; 
Lynch, 2004; Yuste & Bonhoeffer, 2001; Matsuzaki et al, 2004; Lau & Zukin, 2007; 
Malenka, 1994; Luscher & Malenka, 2014). Slightly different is presynaptic LTP 
that does require neither NMDAR receptors activation nor postsynaptic factors, but 
seems to be initiated by an activity-dependent rise in extracellular calcium within 
the presynaptic terminals. The cascade is responsible for the increase in glutamate 
release (Malenka & Bear, 2004; Nicoll & Schimtz, 2005). Three different forms of 
long-term depression are, instead, identified in the mammalian brain: NMDAR-
dependent LTD, metabotropic glutamate receptor-dependent LTD and 
endocannabinoid-mediated LTD. 
NMDA-dependent LTD, like presynaptic LTP, requires repeated activation of the 
presynaptic neuron at low frequencies but not the postsynaptic activity (Malenka & 
Bear 2004; Carroll et al, 2001). Conversely, metabotropic glutamate receptor-
dependent LTD requires either postsynaptic calcium influx through voltage-gated 
ion channels and postsynaptic group I mGluR activation (Malenka & Bear, 2004; 
Ito, 1989). Endocannabinoid-mediated LTD, that recently has received more 
attention than the others, has been recognized at many glutamatergic and 
GABAergic synapses: it is well-established that a sustained postsynaptic calcium 
influx is necessary to trigger the synthesis of the endogenous endocannabinoid 
that retrogradely bind the presynaptic CB1 receptors and depress neurotransmitter 
release (Wilson & Nicoll, 2002). 
Very little is known about the mechanisms of long-term plasticity in the Accumbens 
synapses and parallelism between the main forms of LTP and LTD in these 
pathways are not simple to do. Recently, NMDAR-dependent LTP and LTD and 
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endocannabinoid-mediated LTD have been reported also in these regions 
(Thomas et al, 2000; Kombian & Malenka, 1994; Schramm et al, 2002; Robbe et 
al, 2002; Hoffman et al, 2003). Electrophysiological experiments it has been 
demonstrated a loss of long-term depression in the cortico-accumbens pathway of 
rats withdrawn from the self-administration of cocaine (Martin et al, 2006; 
Moussawi et al, 2009; Knackstedt et al, 2010); in particular the impairment in long-
lasting depression endured only in the subpopulation of rats that developed 
uncontrolled intake (Kasanetz et al, 2010). 
 
Growing evidence suggests the crucial role of the endocannabinoid system in the 
neuroadaptations induced by the prolonged use of drugs (Gonzalez et al, 2005; De 
Vries et al, 2005; Parolaro et al, 2005; Rodríguez de Fonseca et al, 2005; Fattore 
et al, 2005; Ameri et al, 1999; Solinas et al, 2008), probably increasing the hedonic 
impact of rewarding stimuli (Mahler et al, 2007; Kirkham 2009; Jarrett et al, 2007; 
Cota et al, 2006; Solinas et al, 2008) by a close interaction with the endogenous 
opioid system (Cota et al, 2006). It important to underline that drugs derived from 
cannabis (marijuana and hashish) are the most common illicit drugs that activate 
mesolimbic neurons and increase the extracellular dopamine level in the nucleus 
accumbens (Gessa et al, 1998; Tanda et al, 1997). 
Components of the endocannabinoid system, in particular the CB1 receptors, are 
widely distributed throughout the brain reward circuit, on axons, cell bodies and 
dendrites (Herkenham et al., 1990, 1991; Tsou et al., 1998; Egertova et al., 2003; 
Solinas et al., 2008). Once activated, CB1 receptors inhibit both GABAergic and 
excitatory synaptic transmission in the hippocampus (Hoffman and Lupica, 2000; 
Sullivan, 1999), prefrontal cortex (Auclair et al., 2000) and nucleus accumbens 
(Hoffman and Lupica, 2001; Robbe et al., 2001). In a work of 2001, Manzoni and 
collaborators, gave evidence for a presynaptic localization of CB1 receptors at the 
excitatory synapses to the medium spiny neurons in the nucleus accumbens. In 
addition they demonstrated that cannabinoid agonists induced long-term synaptic 
depression in the nucleus accumbens. By using both extracellular field potential 
and patch-clamp recordings, Robbe and colleagues (2002) explored the 
involvement of the endocannabinoid system in the prefrontal cortex-nucleus 
accumbens synaptic plasticity. They showed that a tetanic stimulation (at biological 
occurring frequencies) of the cortical glutamatergic afferents induces a long-term 
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depression in the NAc. Endocannabinoids may exert a retrograde modulation of 
the synaptic transmission, by the activation of the metabotropic glutamate 5 
(mGlu5) receptor which caused an increase of postsynaptic calcium (Zhang et al., 
2011; Lerner et al., 2012; Freestone et al., 2013); this deployment of calcium lead 
to a postsynaptic release of endocannabinoids which retrogradely activated the 
presynaptic CB1 receptors (Robbe et al., 2002). Once activated, CB1R stimulation 
suppressed glutamate release either transiently (short term depression, STD) or 
persistently (long term depression, LTD), (Kano et al., 2009; Ohno-Shosaku et al., 
2012; Katona et al., 2012; Castillo et al., 2012; Piomelli, 2014; Gao et al., 2010; 
Gerdeman et al., 2002; Younts et al., 2013).  
In vivo delta (9)-tetrahydrocannabinol (THC) administration reduced the 
endocannabinoid-mediated long-term depression in the mouse cortico-accumbens 
synapse (Robbe et al., 2003) maybe due to a reduction of the coupling efficiency of 
CB1 receptors to Gi/o transduction proteins (Mato et al., 2005).  
CB1 receptor activation also modulated cortical excitatory synaptic transmission 
(Wilkison et al., 1982; Pontzer et al., 1986; Wallace et al, 2003). In vitro studies 
found that CB1 receptors are differentially expressed, with highest levels of 
expression in layers II, III and V. In particular, it was reported that cannabinoids can 
both balance directly GABAergic and glutamatergic transmission, but also increase 
the spike probability of pyramidal neurons in the layers 2/3 (Fortin et al., 2004; 
Barbara et al., 2003). Acute treatment with WIN 55, 212-2, suppressed evoked 
excitatory postsynaptic responses recorded from layer V pyramidal neurons 
(Auclair et al., 2000). Similar results were obtained by Fortin and Levine, in the 
2007: application of WIN 55, 212-2 depressed excitatory but not inhibitory post 
synaptic currents in the pyramidal neurons of the layer V, while the stimulation of 
the layer V, but not the layers II and III, evoked cannabinoid-sensitive synaptic 
currents; these results suggest that only a subset of glutamatergic inputs express 
cannabinoid receptors. Altogether these studies underlined the involvement of 
cannabinoid system in the modulation of cortical functions, showing different 
effects on excitation and inhibition across the layers, in particular layer V that may 
serve to decrease the efficacy of a subset of excitatory inputs.  
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Chapter 5  
Overview of the techniques 
 
5.1 Self-administration paradigm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
The reinforcing properties of substances of abuse are considered to underlie the 
risk of abuse liability in humans (Balster & Bigelow, 2003; Panlilio & Goldberg, 
2007). To investigate these properties have been developed three main animal 
models of human drug abuse: drug discrimination, conditioned place preference 
and self-administration paradigms (Ator & Griffiths, 2003; Carter & Griffiths, 2009; 
Sanchis-Segura & Spanagel, 2006; Tzschentke, 1998). For our study we used the 
intravenous self-administration model, initially developed in non-human primates by 
Picture 13 Animal self-administration is a form of operant conditioning where the reward is a drug, 
administered remotely through an implanted intravenous catheter. Animals can readily detect the contingency 
between an instrumental response ( in this case, lever press) and the delivery of the drug and respond in an 
operant manner to obtain the drug. [www.med-association.com; Intravenous Self-Administration of Drugs of 
Abuse in Mice, Brown et al. 2012] 
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Weeks and collaborators (1962). Thus, animals can readily detect the contingency 
between an instrumental response (such as a nose poke or, in our case, lever 
press) and the delivery of the drug, (in our case, an intravenous infusion of BZY) 
and respond in an operant manner to obtain the drug (Clark et al, 1961; Weeks, 
1962). Therefore, the substance is considered reinforcing if it is able to maintain 
the self-administration behavior.   
Self-administration paradigm appears to be good correspondence between 
humans and animals in terms of pattern of drug intake: in fact, usually, drugs that 
are abused by humans maintain responding behavior in animals, while drug 
without reinforcing properties (as hallucinogenic drugs), that do not maintain the 
animals behavior, generally are not abused by humans. The advantages to use a 
self-administration paradigm is the fact that the drug is self-administered instead 
experimenter-administered; in this way the schedule of reinforcement can be 
changed and an accurate measurement of the quantities of drug consumed and 
the pattern of infusions can be get.   
To perform self-administration paradigm generally rodents are preferred, although 
also others species are employed, such as dogs, cats and non-human primates. 
The most common routes of drug administration are intravenous and oral, but 
intracerebroventricular, intracranial, inhalation, intragastric and intramuscular has 
been also used although it is more advisable to use route comparable to that used 
by humans. For example, intravenous route is used preferably for studies with 
cocaine and heroin while studies with alcohol typically use an oral route of 
administration. The advantages using intravenous route is to avoid the problems 
related to first pass metabolism or taste and to produce rapid increase in blood and 
brain drug level.  
Self-administration model can imply the use of different schedule of reinforcement. 
In the simple fixed ratio schedule, it is necessary a completion of a fixed number of 
operant responses (fixed by the experimenter) by the animal to obtain the infusion 
of drug. The number of ratio is fixed during the session but can be increased 
between the sessions, during training procedure. There is, in this way, a direct 
relationship between the actual response and drug delivery. Different schedules 
can be used for the investigation of different aspects of drug addiction. More 
complex schedules of reinforcement are the progressive ratio schedule (PR), 
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(Gardner, 2000; Rowlett, 2000; Richardson & Roberts, 1996) and the choice 
procedure (Ward et al, 2005).  
In the animal self-administration literature, the rates of responding on an operant 
lever (active lever) that leads to the delivery of the drug are reported; this measure 
is, in most cases, compared with the responding on a second operant lever 
(inactive lever) on which responding has no scheduled consequences. Generally, a 
drug is considered reinforcing if the responding on the active lever significantly 
exceeds the responding on the inactive lever. In studies where a negative control is 
included, self-administration is identified as responding for the drug which 
significantly exceeds responding for the negative control for saline.  
Since the self-administration paradigm has been designed, new progresses have 
been done to investigate the reinforcing properties of drugs: using the binge self-
administration model, animals given prolonged access to drug (6 hours); in this 
way it is possible to understand the propensity of abuse and the escalation pattern 
of drug intake (Ahmed & Koob, 1998). Another variation from the basic model is the 
self-administration under punishment that mimics the human compulsive use of 
drug despite the negative consequences.  
However, one must remember that drug-self-administration model measures only 
one of many factors that can contribute to abuse liability that is drug reinforcement 
properties. Thus integrating data from pre-clinical and clinical abuse potential 
models will provide a more accurate assessment of abuse liability risk. 
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5.2 Extracellular field recordings 
 
 
 
 
 
 
 
 
 
 
 
 
Prolonged use of drugs is responsible of the reorganization of neural circuitry in the 
reward areas resulting in changes in the synaptic strength/plasticity, the best 
candidates of which are various form of long-term potentiation (LTP) and 
depression (LTD) (Hyman and Malenka, 2001). The demonstration of synaptic 
plasticity at excitatory synapses of the mesocorticolimbic dopamine system, the 
correlative changes in glutamate AMPA receptors expression and single unit 
responses to glutamate after in vivo exposure to drugs of abuse support a role for 
long-term plasticity in the development of addiction (Zhang et al., 1997; Carlezon 
and Nestler, 2002; Thomas and Malenka, 2003).  
The best method to investigate synaptic activity at the network level is 
electrophysiology. Different types of electrophysiological recording techniques 
exist: intracellular (for example patch-clamp), extracellular (field potentials) and 
planar patch clamp recordings.  
In our work, we used field potentials recordings, which allowed the detection of 
local current sources generated by simultaneous activation of a large number of 
nearby neurons, within a small volume of nervous tissue, during the electrical 
stimulation intra-area or of the relative efferents. Evoked action potentials can 
Picture 14 After recovery, slice is transferred to a recording chamber on the microscope and submerged 
beneath continuously flowing aCSF. Stimulating- and recording- electrodes are placed on slice in target areas 
and finally the signal detected by an amplifier and collected.  [Gary L. Westbrook " Seizures and Epilepsy" 
adapted by Konnerth, 1990)] 
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produce a voltage changing that can be detected using a recording microelectrode, 
fill with artificial cerebrospinal fluid (aCSF) and place sufficiently far from local 
individual neurons. This signal is then low-pass filtered to obtain field potential that 
can be displayed and recorded on an oscilloscope (Buzsaki et al., 2012).  
Therefore, the field is defined as the contribution of all ionic processes because 
any single excitable membrane can contribute to the extracellular field recordings. 
Responsible of the strongest currents across the neuronal membranes, fast action 
potentials are detected as spike in the extracellular medium. However, also the 
slow fluctuations of glia cells, responsible of non-synaptic events and voltage-
dependent regenerative calcium spikes, can be detected and cannot separate in 
the field recordings (Hirsch et al., 1995; Schiller et al., 2000; Polsky et al., 2004; 
Larkum et al., 2009Vanhatalo et al., 2004; Hughes et al., 2011; Poskanzer and 
Yuste, 2011).  
Furthermore, it is useful to consider the different contribution of various cell types to 
the field potentials: a bigger pyramidal neuron with long thick apical dendrites 
generates strong dipoles then a smaller interneuron or astrocyte. But in those 
tissues in which the extracellular medium is homogeneous, both the spatial 
alignment and the temporal synchrony between all neurons and glia cells are 
important for the generation field potentials (Buzsaki et al.,2003; Linden et al., 
2011).  
The main properties of the field potentials waveform, amplitude and frequency, 
depend of the various characteristics of brain tissue. Moreover, the larger distance 
between the recording electrode and the current source prevents the correct 
measurement of field potentials.  
For decades, extracellular field recording has been considered an efficient method 
to assess synaptic transmission and plasticity in different brain regions. The 
advantageous of extracellular recordings, relative to intracellular method, is the 
healthy stabile recordings for a long period, also several hours, that results useful 
for plasticity studies.   
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Chapter 6  
Benzydamine self-administration 
 
6.1 Abstract 
 
Rationale Use of illicit drugs by young and vulnerable people is an expanding 
cultural phenomenon, but in recent years, there has been a dramatic increase in 
prescription drugs misuse. Some medications, in fact, have psychoactive 
properties and are sometimes used for recreational reasons and non therapeutical 
purpose. The abuse of BZY, a non-steroidal anti-inflammatory drug (NSAID), has 
been object of increasing concern in Brazil and in other Country in Europe, also in 
Italy. As reported in many drug forums, BZY behaves principally as an 
hallucinogen. The first aim was to determine BZY abuse liability, assessing the 
reinforcing properties using an operant self-administration procedures.  
Materials and methods Indipendent groups of rats with intravenous catheters were 
given the possibility to self-administer different doses of BZY (250, 500 and 1000 
μg/kg per infusion) under two conditions: naïve or drug-experienced. Naïve animals 
have not previously subjected to particular experimental situation, while 
experienced animals have exposed previously to cocaine and heroin, before 
training with BZY. After training, dose-effect curve (125, 250, 500, and 1.000 μg/kg 
per infusion) were calculated. 
Results  We found that BZY has a powerful reinforcing effect and that this effect is 
greatly facilitated in animals that already had substance experience, having 
previously self-administered heroin and cocaine, indicating cross sensitization 
between BZY and other common drugs of abuse.  
Conclusion The present study confirms, at a preclinical level, the reinforcing 
properties of BZY. This results may suggest that also in human, the subjects more 
prone to BZY consumption are those which had previous experienced other drugs.  
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6.2 Introduction 
 
BZY, available as the hydrochloride form, is an anti-inflammatory drug, that taken 
at high dosages of 500 mg to 3000 mg, behaves as a psychoactive substance and 
a central nervous system stimulant. Considering the users' descriptions found in 
several online forums, BZY may be principally considered an hallucinogenic drug. 
Hallucinations may be explained considering the serotonergic hypothesis: it is 
known in fact that other hallucinogenic drugs as LSD, mescaline, DMT and 
psilocybin act as agonists of 5HT2A receptors present in certain areas of the CNS. 
Notably, BZY molecule has a structural affinity with serotonin, because the 
presence of the indole compound, (Opaleye et al, 2009).  
Elizado Carlini of CEBRID (Centro Brasileiro de Informações sobre Drogas 
Psicotrópicas, Departamento de Medicina Preventiva da UNIFESP, Universidade 
Federal de São Paulo) has proposed a different hypothesis: BZY, taken at high 
doses, could increase the release of Dopamine in the brain and consequently 
activate the limbic system. In this way, the emotional experiences could be recall 
and changed so they are perceived altered, (Mota et al, 2010). 
In this framework, it is necessary to consider that the derivatives of amphetamine, 
as methamphetamine and MDMA, have hallucinogenic properties as LSD, but also 
reinforcing properties; in fact while there is no evidence for animal self-
administration of primary hallucinogenic substances like LSD (Deneau et al, 1969), 
animals self-administer amphetamine derivatives (Fantegrossi et al, 2002; Lamb et 
al, 1987; Schenk et al, 2003, 2007; Sannerud et al, 1996).   
Here we investigated the reinforcing properties of BZY in an animal model of 
intravenous self-administration. In particular we wanted to test the capacity of this 
substance to develop and mantein the self-administration behavior in rats, using 
both naïve and drug experienced animals. Notably, BZY is frequently used in 
association to other ‘main’ drugs as alcohol or THC, or to substitute drugs 
temporarely not available. Moreover, different cases report of volontary BZY use 
refers to addict.  
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6.3 Materials and methods 
 
6.3.1 Animal 
 
The study was conducted using 23 male Sprague Dawley rats (Harlan Italy, San 
pietro Natisone, Italy) weighing 275 g at their arrival in the laboratory. All rats were 
housed, two per cage,  for 7-10 days before the surgery,in a dedicated 
temperature- (20±2 °C) and humidity- (70%) controlled rooms, with free access to 
food and water (except during the test sessions) under a 14 h dark/ 10 h light cycle 
(light off at 7 am). 
All procedurs were in accordance with the Italian Law on Animal Reserch (directive 
2010/63/EU of the European Parliament and of the Council) and with the 
guidelines for the care and use of laboratory animals issued by the Italian Ministry 
of Health.  
 
6.3.2 Drugs 
 
 Rompum 20 mg/ml injectable(Bayer® HealthCare pharmaceuticals): 2.33 
mg of muscle relaxant was administered intraperitoneal(each ml contains 
23.32 mg xylazine hydrochloride, corrispondent to 20 mg of xylazine 
equivalent base). 
 Zoletil 100 injectable anaesthetic/sedative (Virbac®, Carros, France). It is a 
combination of a dissociative anethetic agent, tiletamine hypochloride (50 
mg/ml), and a tranquilizer, zolazepam hypochloride 850 mg/ml).Each rat 
were anesthetized with an intra-peritoneally injection of 0.56 ml/kg of Zoletil. 
 Baytril antibacterial injectable solution 2.27% for veterinary use (Bayer®, 
KVP Pharma + Veterinär Produkte Gmbh, Kiel, Germany); it was 
administered intravenous: 15mg/0.1 ml after surgery and 0.4 mg/ml daily (1 
ml injectable solution contains 50 mg enrofloxacin).  
 Heparin sodium 12500UI/0.5ml (Marvecs Services, Agrate Brianza, Italy). 
Catheters were flushed daily with 0.1 ml of a sterile saline solution 
containing 25 IU heparin. 
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 Tiopental sodium (Pharmacia Italia, Milano, Italia).Each rat were 
administered intravenously with 40 mg/kg. 
 Benzydamine hydrochloride (Sigma Aldrich®), wasdissolved in isotonic 
NaCl (0.9% w/w saline in water), and infused at a volume of 40 μl over 4 sec 
at a dose of 250, 500 and 1000 µg/kg/infusion. 
 Cocaine HCl (National Institute on Drug Abuse) was dissolved in sterile 
saline (isotonic NaCl 0.9% w/w saline in water), and infused at a volume of 
40 μl over 4 sec at a dose of 400 µg/kg/infusion. 
 Heroin (diacetylmorphine HCl,(National Institute on Drug Abuse)was 
dissolved in sterile saline (isotonic NaCl 0.9% w/w saline in water) and 
infused at a volume of 40 μl over 4 sec at a dose of 25µg/kg/infusion. 
 
6.3.3 Intravenous surgery 
 
Animals were deeply anesthetized with an intraperitoneal injection of Zoletil 100® 
and Rompum® and an indwelling catheter (SILASTIC®  tubing, Plastics One, 
Roanoke, VA), (0.51 mm inner diameter, 0.94 mm outer diameter, and 11 cm 
length, sheathed at 3.4 cm from its proximal end by a 5 mm length of heat-shrink 
tubing), was surgically implanted into the right jugular vein. The catheter was 
secured to the vein with surgical silk suture and passed subcutaneously and 
externalized through a small incision at the nape of the neck and connected to an 
L-shaped 22 Gauge cannula. The cannula was then secured to the rat’s skull using 
dental cement and stainless steel screws. After surgery, the rats were given baytril 
0,1 ml intravenously. Catheters were flushed daily with a solution containing baytril 
and heparin to mantein patency.   
 
6.3.4 Self-administration chambers and experimental context 
 
The apparatus consisted of SA chambers (28.5 cm length, 27 cm width and 32 cm 
height) made of trasparent plastic (front and rear walls), aluminium (sidewalls and 
ceiling) and stainless steel (grid floor). Plastic trays covered with pinewood shaving 
were placed under the grid floors. Each chamber was equipped with two 
retractable levers, positioned on the left hand wall 12.5 cm apart and 9 cm above 
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the floor, three cue lights (red, yellow 
and green), positioned above each 
lever, and a counterbalanced arm 
holding a liquid swivel.  
The SA chambers were placed within 
sound- and light- attenuating cubicles. 
Each cage was connected via an 
electronic interface to a syringe pump 
(Razel Scientific Instruments, St. 
Albans, VT, USA), in turn connected 
to a computer. Chambers, accessories and 
electronic interfaces were purchesed from 
EATEL s.r.l. (Rome, Italy) and custom-
developed control software from Aries 
System S.r.l. (Rome, Italy).  
The infusion line consisted of a length of 
silastic tubing protected by a stainless steel 
spring and connected (through the liquid swivel and another length of silastic 
tubing) to a syringe positioned on the pump (which was programmed to work at an 
infusion rate of 10 µL/s. 
 
Picture 16 Each operant-chamber is placed within a cubicle, connected either to a syringe pump, throughout 
an electronic interface, and to a computer software.  [www.med-
associates.com/drug_del/rmouseselfadmin.htm]  
 
 
 
Picture 15 Self-administration chamber for 
rats. The chamber is assembled with black 
aluminium walls and a transparent front 
door. The chambers employ a stainless-
steel grid floor that allows waste to collect in 
a removable tray. All floor components 
(including the grid) are removable. Inside the 
chamber are present two extractable levers. 
On the right external side of the chamber is 
fixed a steel arm that supports a swivel, for 
the infusion line. 
[http://www.instechlabs.com/Infusion/system
s/selfadministration-rat.php] 
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6.3.5 Self-administration procedures 
 
After surgery, the rats were housed in tranparent plastic cages (40 cm length, 24.5 
cm widht and 18 cm height) with stainless steel tops and flat bottoms covered with 
ground cornocob bedding.  
Before the start of the experiment the animals were divided and assigned to one of 
two testing conditions: naïve- and experienced- group. The two groups underwent 
two different experimental procedures: all animals in the 'naive' group underwent 
an experimental procedure in which they were trained to self-administered only 
BZY.  
On the contrary, the animals in the 'drug-experienced' group underwent two 
different training schedules: in the first one they were trained to self-administered 
cocaine and heroin, while in the second phase, after a period of extinction, they 
were given the chance to self-administered BZY. This because the virtual totality of 
BZY recreational use cases are reported to involve individuals with previous 
substance abuse history, sometimes to substitute other drugs when are absent.   
For both groups, training procedure began 1 week after surgery. Immediately 
before the start of each session, every animal were transferred to the self-
administration chamber and their catheters connected to infusion lines filled with 
the appropriate drug solution. At the end of each session, animals were re-
transferred to their standard cages. All test sessions lasted 3 hours and took place 
during the dark phase, between 9 am and 5 pm, 7 days a week. 
During the self-administration sessions the doors of the cubicles were kept closed 
to prevent noise that could disturb the animal. At the start of each session, two 
levers were extended in each cage: only one of the two was active and triggered 
an infusion of BZY delivered over a period of 3 seconds; the second lever had not 
direct consequences except resetting the counter on the active lever. Within each 
group, left and right levers were counterbalanced for the active and inactive status. 
Above the active lever were presented three light cues that were turned on only 
during extension of the lever. No other light cue was provided. 
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Picture 17 Training scheme. Animals of both groups received 14 training sessions. Under the squares are 
reported the number of consecutive responses required to obtain a single infusion: FR1 to FR5, in the showed 
correspondence.  
Training procedure for ‘naïve’ group consisted of fourteen sessions under a fixed 
ratio schedule progressively incresed from 1 to 5 (days 1-7 FR1, day 8 FR2, day 9 
FR3, day 10 FR4, days 11-14 FR5); fixed ratio means that a single infusion was 
raised only after a specified number of responses. 
After the completion of each task, a 40 sec time-out period was presented (i.e. for 
that no cage element was on, as levers or light cues).  
Five minutes after the beginning of each session, animals that had not 
spontaneously self-administered at least one infusion were placed with their 
forepaws on the active lever so as to trigger a priming infusion. Priming infusions 
were administered again at 1 hour to animals that had not spostaneously self-
administered at least two infusions during the first 60 min of session and at 2 hours 
to animals that had not spostaneously self-administered at least two infusions 
during the first 120 min of session. On FR5 sessions (days 11-14), priming 
infusions were given only to rats that failed to self-administer at least one infusion 
within the 0-5 min period. These experimenter-induced lever presses were 
opportunely subtracted from the total.  
The animals were divided, at the beginning of the experiment, in independent 
subgroups, following three different doses of BZY: 250 µg/kg, n=4; 500 µg/kg, n=4; 
1000 µg/kg, n=4. The rats were allowed to self-administer a maximum of 50 
infusions of BZY per session.  
After the training period, the animals underwent other 4 session (15-18), in which 
each rat have received the possibility to self-administered (following a latin square 
design) three additional doses of BZY than the training dose. In this way, all 
animals were tested for responding to four different dosages (125 mg/kg, 250 
mg/kg, 500 mg/kg, 1000 mg/kg). These sessions were conducted under a FR5 
schedule of reinforcement and without drug priming administration. 
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The animals of 'experienced' group underwent two different self-administration 
procedures. During the training phase, beginning one week after surgery, the 
animals received the possibility to self-administer cocaine (400.0 μg/kg) and heroin 
(25.0 μg/kg), made available on alternate days. The two substances were paired 
with different levers, in a counterbalanced fashion (left vs right, drug on the first 
session).  Training procedure consisted in fourteen sessions under a fixed ratio 
schedule progressively increased from FR1 to FR5. The animal that had not 
spontaneously self-administered at least one infusion after 5 minutes from the 
beginning, two infusions after 60 minutes and three infusions after 120 minutes, 
had received a priming infusion, as the animals of the 'naive' group. After the 
training phase, the animals of the experienced group had undergone 10 days of 
extinction during which they were transferred to the self-administration chambers 
and their catheter connected to infusion lines, filled only with saline. After this 
period of twenty four days, the animals were transferred in a different experimental 
room and had undergone fourteen days of BZY self-administration, with the same 
protocol received from 'naive' group. 
 
6.3.6 Catheter patency test 
 
After the last test session all rats, of both groups, were undergone a catheter 
patency test consisting in the administration of 0,1 ml saline with 40 mg/kg 
Tiopental Sodium (see the section ‘Drugs’), in a single intravenous bolus. Rats that 
did not became ataxic within 5 s after test were excluded from the statistics.  
 
6.4 Data analysis and statistics 
 
In vivo data were analyzed using both three- and four-way mixed ANOVA for 
repeated measures, with lever (active vs inactive) and session treated as within 
factors, while dosage and experience (naïve vs drug-experienced) as between 
factors. Data were analyzed using IBM SPSS 20 statistical software.   
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Chapter 7  
Field recordings 
 
7.1 Abstract 
 
Rationale The recent theories of addiction have focused on particular aspects of 
drug-induced neuroadaptations that may explain craving, seeking and taking 
behavior and relapse after a period of withdrawal. Alterations in cortico-accumbens 
glutamatergic pathway is considered very crucial in the development of drug 
addiction. 
The second aim of our study was to assess if BZY was able to induced long-lasting 
modification of basal glutamatergic cortico-accumbens transmission directly or by 
the involvement of other signiling ie the dopaminergic and endocannabinoid 
system. 
Materials and methods Extracellular field recordings were made in parasagittal 
slices containing both nucleus accumbens and infralimbic cortex, from adult male 
rats. BZY was applied in the bath perfusion and the field excitatory post-synaptic 
potentials (fEPSP), elicited by stimulating the glutamatergic cortical afferents at the 
border of the accumbens, were recorded in the ventral striatum. The D1R 
antagonist SCH23390 and the CB1R antagonist AM-251 were added at the final 
concentration to the superfusion medium. 
Results Upon BZY application, fEPSP resulted in a dose-dependent amplitude 
reduction in both naïve and drug-experienced rats, although the effects were 
potentiated in slices from animals that had undergone a previous experience with 
heroin and cocaine. Also, BZY superfusion right before the HFS train diminished 
the LTP-like response of NAcc neurons compared to controls. Due to the alteration 
of short term plasticity we report that BZY induced LTD by a presynaptic 
mechanism. Furthermore this LTD-like response was significantly reduced by the 
CB1 receptor antagonist AM 251but not affected by the dopamine D1 receptor 
antagonist SCH23390.  
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Conclusion These results provide the first evidence of BZY effect on central 
nervous system, suggesting the interaction with cannabinoidergic system.  
 
7.2 Introduction 
 
Prolonged drugs use is responsible of synaptic plasticity and aberrant 
neuroadaptations involved in the uncontrolled drug-seeking and drug taking 
behavior (Robinson & Berridge, 1993; Kalivas, 1995; Wolf, 1998; Hyman & 
Malenka, 2001; Nestler, 2001; Carlezon & Nestler, 2002; Everitt & wolf, 2002; 
Hyman et al, 2006). The drug-dependent reorganization of neural circuitry can be 
mediated by different mechanisms, included forms of long-term potentiation (LTP) 
and long-term depression (LTD) (Kalivas, 1995; Wolf, 1998; Clark & Overtone, 
1998; Martin et al, 2000; Bear, 1996). All excitatory synapses in the mammalian 
brain express this form of plasticity, although the mechanisms differ among 
different brain regions. Notably, LTP and LTD can be expressed at excitatory 
synapses in the nucleus accumbens and both require the activation of NMDA 
receptors but not dopamine receptors.   
Numerous studies have revealed that while the dopamine system is involved 
principally in the establishment of drug taking behavior, in a later phase, in which 
the addiction behavior is developed, drug-seeking and drug-taking behavior are 
depended on the glutamatergic prefrontal afferents to the nucleus accumbens (see 
chapter 4). Growing evidence support the involvement of the endocannabinoids 
system in the neuroadaptations following prolonged drug use. Principally, it is 
considered crucial the retrograd mechanism by which an increase in intracellular 
calcium concentration, after a sustained postsynaptic depolarization, is responsible 
of the release of endogenous endocannabinoids that bind CB1 receptor localized 
on the presynaptic membrane, with consequent reduction of the neurotransmitter 
release.  
After demonstrating that BZY is able to develop and maintain self-administration 
behavior, we investigated the in vitro effects of BZY of the glutamatergic cortico-
accumbens synaptic activity, when it was added at the final concentration to the 
perfusion aCSF. It was used, added in perfusion fluid, either dopamine antagonist 
SCH23390 and endocannabinoid antagonist am-251 to investigate the involvment 
of these two neurotrasmission systems.  
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7.3 Materials and methods 
 
7.3.1 Animal 
 
The study was conducted using 23 male Sprague Dawley adult rats housed in a 
dedicated temperature- (20±2 °C) and humidity- (70%) controlled rooms, with free 
access to food and water, under a 12 h light/ 12 h dark cycle (light on at 7 am). 
Drug-experienced rats (n=5, P80/90, previously undergone alternate days cocaine 
and heroin self-administration) were given 5-7 days of rest in their home cages 
before they were sacrificed to collect brain slices. 
All procedurs were in accordance with the Italian Law on Animal Reserch (directive 
2010/63/EU of the European Parliament and of the Council) and with the 
guidelines for the care and use of laboratory animals issued by the Italian Ministry 
of Health.  
 
7.3.2 Drugs 
 
 Halothane (Sigma Aldrich®). 
 Benzydamine hydrochloride (30 μM e 100μM, Sigma Aldrich®). 
 Picrotoxin, GABAA antagonist (100 μM, Abcam). 
 AM251, CB1 receptor antagonist (2 µM, Abcam). 
 SCH23390, D1 receptor antagonist (1 µM, Abcam) 
 
7.3.3 Slice preparation 
 
Each animal was completely anesthetized with halothane (2-bromo-2-chloro-1,1,1-
trifluoroethane) and decapitated. Parasagittal NAc (Nucleus Accumbens) slices 
(300 µm thick) were prepared from both hemispheres using a Leica 1200 T 
vibratome. Throughout the procedure, the tissue was maintained in a room 
temperature choline cutting-solution (KCl 2,5 mM, NaH2PO4 1,25 mM, MgSO4 10 
mM, CaCl2 0,50 mM, Choline 120 mM, NaHCO3 26 mM, Glucose 10 mM), which 
was bubbled continuously with 95% O2 – 5% CO2.  Slices were stored at least 1 
hour at 35°C in artificial Cerebro-Spinal Fluid, aCSF (NaCl 126 mM, KCl 1.25 mM, 
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NaH2PO4 1.25 mM, MgSO4 2 mM, CaCl2 2 mM, NaHCO3 26 mM, Glucose 10 
mM), equilibrated with a 95% O2 – 5% CO2 mixture. 
 
7.3.4 Field recordings 
 
After the recovery period, slices were transferred to a recording chamber and 
submerged beneath continuously flowing (3/3.5 mL/min) aCSF at a temperature of 
30-32 °C. Because of the presence of strong GABAergic inhibition on the NAc, 
picrotoxin (100µM) was added in the aCSF for all experiments.  
Extracellular recordings were obtained using glass micropipettes filled with aCSF,  
from the region of the Nucleus Accumbens core, using the anterior commissure 
and lateral ventricles as anatomical markers. Field EPSPs (excitatory post-synaptic 
potentials) were evoked by prelimbic cortical afferents stimulation, (square wave 
current of 25µs duration erogated at a frequency of 0.03 Hz), placing a bipolar 
electrodes at the prefrontal Cortex-Accumbens border.  
 
 
 
Picture 16 Parasagittal slices of rat brain (the rat brain atlas of Paxinos and Watson). During field recordings, 
the recording microelectrode was placed in the nucleus accumbens while the stimulation electrode was placed 
on the boundary of the accumbens, to stimulate the glutamatergic efferents from the prefrontal cortex.  
All recordings were performed using a Multiclamp 700b amplifier (Axon 
Instruments), filtered a 2 kHz and digitized at 10 Khz, converted by a Digidata 
1322A (Axon Instruments),collected and analyzed using a Clampex 9.2 software. 
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Picture 17  Images of electrophysiological setup that has been used for the recordings reported in this 
work.  
 
The stimulus was applied every 30 sec. After the stabilization of the evoked fEPSP, 
control baseline was recorded for 15 minutes, at 50-60 % of the maximal response. 
After baseline, to test whether BZY could induce per se a long-term change of the 
glutamatergic cortico-accumbens synapses, BZY 30 µM was added at the final 
concentration to the perfusion aCSF and the amplitude of the fEPSP was recorded 
for 30 minutes. Slightly different the protocol used for BZY 100 µM:  the slice was 
perfused for 10 minutes with aCSF added with BZY and then the amplitude 
recorded for 30 minutes in wash condition. This because BZY 100 µM caused a 
severe depression of the synaptic response. To exclude that this severe 
depression of the synaptic response could be due to non-specific toxic effect of 
higher doses of BZY (100 µM), current pulses of higher intensity were delivered at 
the end of the experiments. 
To investigate short-term regulation of neurotransmitter release by BZY, paired 
stimuli were delivered at 120 ms interstimuls intervals and the paired pulse ratio 
(PPR) was measured as the ratio of the amplitude of the second on the first 
postsynaptic response. 
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7.4 Data analysis and statistics 
 
For electrophysiological experiments, the experimental comparison was between 
the magnitude of the baseline responses and the magnitude of the responses in 
BZY. ANOVA for repeated measures was used with time as the within factor.  Data 
from paired pulse experiments were analyzed using paired samples t-test. Data 
were analyzed using IBM SPSS 20 statistical software. 
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Chapter 8 
 Results 
8.1 Benzydamine self-administration 
 
3 
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For the behavior, the animals of both group, naïve and drug experienced, self-
administered three different doses of BZY (250 µg/kg; 500 µg/kg; 1000 µg/kg, 
during a period of training of 14 days, with an increase of the fixed ratio from 1 to 5 
(FR1 1th - 7th days; FR2 8th day; FR3 9th day; FR4 10th day;FR5 11th – 14th day). 
The rats of both group acquired BZY self-administration behavior, as it’s shown in 
the panels of the picture 20, in which the number of lever pressing on the active 
lever is higher than the number of presses on the inactive one, as a function of FR. 
The three-way ANOVA yielded, for both group, significant effects of sessions 
(naïve [F(5,809) p<0.001] drug experienced [F(4,014) p<0.001]), lever (naïve 
[F(8,555) p<0.017] drug experienced [F(20,110) p<0.002]) and the interaction 
lever*session (naïve [F(5,940) p<0.001] drug experienced [F(5,334) p<0.001]). 
Regarding the interactions session*training dose and lever*session*training dose, 
the three-way ANOVA (for repeated measure on the factor session) shows, for 
naïve group, a dose-dependent acquisition of lever pressing behavior 
(session*training dose [F(2,602) p<0.001]; lever*session*training dose [F(2,635) 
p<0.001]), while drug-experienced rats do not display it, working on lever pressing 
without any statistically significant difference between dose groups.  
In the picture 21 we compare the number of lever pressing for  both groups, for all 
doses; a three-way ANOVA (for repeated measures on the variable session) 
pointed out a significant effect of session [F(9,675) p<0.001]. There is not 
significant session*experience*training dose interaction. As we can observe, at the 
lower dose (250 µg/kg) only the animals from the drug experienced group show the 
self-administration behavior, while it is almost absent in the naïve group. Instead, at 
the higher dose (1000 µg/kg), there is the overlap between the behavior displayed 
by the animals of the two groups. A four-way ANOVA yielded a significant effect of 
experience [F1,21=7.721; p=0.013] and lever*experience interaction [F1,21=5.629; 
p=0.03] on the lever pressing behavior. This effects states that the drug 
experienced rats’ operant behavior is more sustained as well as more readily 
acquired.  Variability observed in the late training phase frames a fluctuating self-
administration behavior interspersed with days of significantly reduced intake.  It’s 
interesting to note that rats which self-administered a great amount of BZY (i.e. 
Picture 20 Mean number (±SEM) of lever presses on the active and inactive levers for rats of naïve- and 
experienced group. Independent sub-groups of rats, for both experimental groups, self-administered 250, 500, 
or 1000 μg/kg per infusion (top, middle, and bottom panels, respectively). The FR was progressively increased: 
FR1 (sessions 1–7) FR2 (session 8), FR3 (session 9), FR4 (session 10) and FR5 (sessions 11-14) 
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about 20 mg/Kg in a single session) showed hypothermia and hypotaxia at the end 
of the session, when they were disconnected from the infusion line and returned in 
their home cages.  
Unfortunately, we were 
not equipped to 
quantitatively measure 
these parameters.  
However, days with 
reduced intake could 
depend on the stacking 
of these undesired 
adverse effects, thus 
resulting in an 
intermittent self-
administration pattern, 
particularly clear for the 
higher dose group. 
 
 
 
 
 
 
Picture 21 Comparison of mean 
number (±SEM) of lever presses on 
the active lever for rats of naïve- and 
experienced group , self-
administered 250, 500, or 1000 
μg/kg per infusion (top, middle, and 
bottom panels, respectively). The 
FR was progressively increased: 
FR1 (sessions 1–7) FR2 (session 8), 
FR3 (session 9), FR4 (session 10) 
and FR5 (sessions 11-14) 
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Picture 22 shows the mean 
number of infusions during 
the sessions 15-18 for the 
dose-response curve. Data 
were analyzed using a three-
way ANOVA (with repeated 
measures as within factor and 
the experience and the 
training dose as between 
factors). The ANOVA 
conducted on the infusion 
data indicated significant 
effects of session [F(3,987) 
p<0.013] but no for interaction 
session*training dose (p<0.1) 
and interaction 
session*experience (p<0.1).  
 
 
 
 
 
 
 
 
 
Picture 22 Dose-response curve for 
the acquisition of Benzydamine self-
administration behavior. Each symbol 
indicates the mean number (±SEM) 
of infusions of Benzydamine on a 
FR5 schedule of reinforcement (i.e., 
mean values calculated for sessions 
15-18) 
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8.2 Field recordings 
 
Bath application of 30 µM BZY for 30 minutes and 100 µM BZY for 10 minutes 
dose-dependently decreased cortico-NAcc fEPSP amplitude by 36,1±6,8% (from 
0,77±0,06 mV to 0,51±0,09 mV, n=7) and 64,8±5,7% (from 0,75±0,07 mV to 
0,27±0,05 mV, n=7), respectively (Fig. 22 a-b).  
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Picture 23 Effect of BZY perfusion on cortico-accumbens glutamatergic fEPSP. a-b) Sample traces at different 
time points of the time-course plot of a representative BZY 30 µM.experiment c) Time plot of normalized fEPSP 
amplitude during perfusion of BZY 30 µM (n=7 slices/3 animals, 30 min) and BZY 100 µM (n=7/3, 10 min).  
 
Repeated measures ANOVA run on data from minutes 15 to 45 showed a 
significant main effect of time [F59,708=20,819; p<0,001], concentration 
[F1,12=42,437; p<0,001], and their interaction [F59,708=4,340; p<0,001].  To 
exclude that this severe depression of the synaptic response could be due to non-
specific toxic effect of higher doses of BZY (100 µM), current pulses of higher 
intensity were delivered at the end of the experiments. In this experimental 
condition the depressed 
fEPSPs recovered to the 
baseline amplitude values 
(data not shown).  
We next investigated short-
term regulation of 
neurotransmitter release by 
measuring PPRs. In control 
condition, extracellular pair 
of stimuli elicited a paired 
pulse depression, a 
reduction of the second 
synaptic response relatively 
to the first (fEPSP2/fEPSP1) 
(Fig. 23). BZY (30 µM) 
decreased PPR (from 
0,85±0,05 baseline to 
0,59±0,03 after 30 min perfusion; n=7; t=4,978; p=0,003) suggesting a presynaptic 
site of action.  BZY (100 µM) completely abolished the fEPSP in many 
experiments, thus it was not possible to consider PPR measured in these 
experiments as meaningful (the resulting ratio yielded PPR values near to 1, data 
not shown). 
Picture 24 Paired Pulse Ratio (PPR) values measured right before 
and after 30 minutes of BZY 30 µM. BZY induced a significant 
reduction in PPR at cortico-accumbens synapses. Representative 
traces are displayed above the histogram. 
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Picture 25 Electrophysiological effect of BZY is enhanced in drug-experienced rats’ brain slices. a) BZY-
induced fEPSP depression in brain slices from naïve (n=7 slices/4 animals) and drug experienced rats 
(n=10/5). b) Representative traces from experiments on brain slices collected from naïve or drug experienced 
rats. Traces were obtained by averaging 4-5 sweeps at each experimental conditions (baseline and during BZY 
perfusion). Values are displayed as mean ± SEM. 
The BZY-induced depression of fEPSP was significantly enhanced in drug-
experienced animals compared to naïve rats (Fig 24). Two way mixed ANOVA for  
repeated measures unveiled a significant main effect of experience [F1,21=9,237; 
p=0,006] and experience*time interaction [F59,1239=3,573; p=0,01], thus depicting 
a sensitization of cortico-accumbens synapses to acute effects of BZY perfusion, in 
drug-experienced rats. 
 
 
Picture 26 BZY is able to induce stable LTD at the cortico-accumbens synapses. a) Mean normalized fEPSP 
amplitude in response to BZY 100 µM perfusion for 8 min (n=5 slices/3 animals) in control condition (open 
circles) and in the presence of the CB1 antagonist AM251 2 µM (filled circles). Note that the  co-perfusion 
significantly reduces the BZY-induced LTD (n=5/5). b) Paired Pulse Ratio values measured at different time 
points (as depicted by numbers) show an induction effect that is denied by the presence of CB1 antagonist 
AM251. * different from BZY baseline (1); # different from BZY end of recording (3). Values are displayed as 
mean ± SEM. 
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As shown in Picture 23, BZY induced a significant reduction in PPR at cortico-
accumbens synapses suggesting a presynaptic mechanism. Similarly, 
endocannabinoids presinaptically reduced glutamate release and mediated LTD at 
glutamatergic synapses on spiny neurons within the basal ganglia nucleus. 
As shown in Picture 25a, bath perfusion of 100 µM BZY for 8 minutes (longer time 
resulted in a drastic reduction of the fEPSP) reduced fEPSC amplitude by 
32,8±2,9% in the last thirty minutes of recordings (from 0,65±0,04 mV to 0,43±0,02 
mV; n=5; t=7,265; p=0,002). Interestigly, stable LTD-like response induced by BZY 
was consistently reduced by the CB1 receptor antagonist AM251 (2 µM) [main 
effect of treatment, F1,8=10,472; p=0,012]. In the presence of AM 251, BZY 
depressed fEPSP by 14,8±5,8% (from 0,75±0,05mV to 0,65±0,08 mV; n=5; 
t=1,814; p=0,144) and the BZY-induced reduction of PPR was fully counteracted 
(from 0,85±0,05 baseline to 0,69±0,06 during BZY alone, t=4,384, p =0,012; from 
0,80±0,03 baseline to 0,88±0,07 BZY in AM251, p=0,342).  AM251 did not affect 
PPR per se (0,81±0,03, p=0,825 vs baseline PPR, data not shown). This result 
suggests that BZY and CB1 agonists may share common mechanisms to inhibit 
excitatory synaptic transmission. Further experiments will be performed to better 
characterize BZY/endocannabinoid interaction. 
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Chapter 9  
Discussion 
 
he present study represents the first investigation of the reinforcing 
properties of the non-steroidal anti-inflammatory drug BZY in an animal 
model of drug abuse and the plastic effects on the glutamatergic plasticity 
in the cortico-accumbens synapses.  
Abuse of BZY is a new but not well-known phenomenon, popular in Brazil and in 
other few Countries and used expecially in the streets context or to substitute other 
drugs, temporarily not available.  
BZY self-administration in the rat model confirms the positive reinforcing effects 
that support the human abuse. We report that, naïve rats (without any drug 
experience or previos self-administration training), self-administered BZY only at 
high doses while at lower doses there is not a significant difference between the 
number of presses on the active lever versus the inactive one. On the contrary, the 
animals with a history of self-administration of heroin and cocaine showed a 
facilitate acquisition of the self-administration behavior of BZY, also at lower dose.  
The differences we found at 250 µg/kg. between the groups may be explained 
considering the previous experience with drugs of abuse. Drugs-experienced 
animals, in fact, previously acquired self-administration behavior and could be 
more familiar with the lever pressing task. However, it may be a consequence of 
the phenomenon of cross-sensitization between cocaine and heroin effects and 
BZY effects. Generally, sensitization is considered as an enduring increase in the 
response to drugs as a consequences of the neuroadaptations elicited by repeated 
exposure (Stewart and Badiani, 1993). Behavioral sensitization that appears to 
results, at least in part, from the experieced-induced adaptations seems to be a 
consequence of the motivational value attributed to cue paired with drugs of abuse 
and also natural rewards (the mesocorticolimbic dopamine system; see Chapter 3). 
Cross-sensitization is a particular type of sensitization considered the 
neurobiological process whereby one type of treatment may potentiate the 
response to another. Several studies have proved the consistency of cross-
sensitization phenomenon either between different classes of drugs of abuse and 
T 
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also between natural reward and psychoactive substances (Robinson and 
Berridge, 1993; Fiorino and Phillips 1999; Nocjar and Panksepp, 2002; Vitale et al., 
2003). Roitman et al. (2002) have demonstrated an increase in dendritic length and 
branching in nucleus accumbens of animal that had undergone a chronic sodium 
depletion that were comparable with those previously described in rodent brains 
sensitized to amphetamine. Moreover, it has been shown that the effects of acute 
and repeated stress can potentiate the effects of cocaine and other addictive drugs 
througha cross-sensitization phenomenon: stress, in fact, may increse drug-
induced mesocorticolimbic dopamine transmission as well as rewarding and 
locomotor activating effects of drugs (Lu et al., 2003; Lett, 1989; Capriles and 
Cancela, 1999; Vezina et al., 2002; Capriles et al., 2003; Saal et al., 2003; Wang et 
al., 2005). Similaly, it has been reported that pre-exposure to opioids can induce 
long-lasting sensitization to opioids and psychostimulants and viceversa, 
pretreatment with amphetamine and cocaine results in long-lasting cross-
sensitization between psychostimulants (DuMars et al., 1988; Vandershuren et al., 
1997, 1999; Kalivas and Weber, 1988; Pierce and Kalivas, 1995).  The behavioral 
results may suggest that also in human, the subjects more prone to BZY 
consumption are those which had previous experienced other drugs.  
 
Extracellular field recording revealed that BZY caused a dose-dependent long-term 
depression (LTD), in both, naïve and drug-experienced rats. In these latters, BZY-
mediated effects  were greater. possibly due to a cross-sensitization phenomenon 
(see above). Indeed, we hypothesized that previuos treatment with heroin and 
cocaine may have caused deep neuroadptations further exacerbated by BZY. 
Similarly to BZY, dopamine, cocaine and amphetamine reduced the evoked 
excitatory synaptic responses at prelimbic cortical-nucleus accumbens synapses. 
This effect was due to the activation of D1 receptors (Nicola and Malenka, 1996)  
However, in our esperiments, D1-like receptor antagonist SCH23390 did not affect 
BZY-induced reduction of the evoked responses (data not shown). Likewise, 
Pennartz and collaborators showed that both LTD and LTP were independent of 
dopamine receptors, although they used an electrical stimulation of the prelimbic 
cortical afferents and not a pharmacological procedure (Pennartz et al., 1993; 
Kombian and Malenka, 1994).  
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The reduction of the paired pulse ratio (PPR) suggest that the BZY-induced 
reduction of cortico-accumbens glutamatergic neurotrasmission is mediated by a 
presynaptic mechanism. It is known that also the endogenous cannabinoids, acting 
on CB1 receptors, reduce spontaneous excitatory synaptic transmission, thorugh a 
presynaptic mechanism, by the activation of K+ conductances (Robbe et al., 2001; 
Robbe et al., 2002). Coherently, immunohistochemical techniques identified the 
expression of CB1 receptors on cortical glutamatergic afferents suggesting a 
presynaptic mechanism. In our study we found that AM-251, a CB1-like receptor 
antagonist, significantly reduced BZY-induced LTD. BZY may stimulate 
endocannabinoid synthesis and release, which in turn reduced glutamate release 
from the cortical terminal. Notably, WIN 55,212,2 induced persistent and long 
lasting field amplitude depression in the nucleus accumbens (Robbe et al., 2002). 
Coherently with these observations, amphetamine-evoked acute depression in the 
amygdala was  in large part mediated by CB1 receptors. In fact, CB1 receptor 
antagonist AM-251 blocked amphetamine-induced LTD, while the same 
phenomenon was mimicked by WIN 55, 212, 2. (Huang et al., 2003).   
Examining the effects of BZY reported in several online forums leap out also 
hallucinogenic properties of this drug. Therefore, BZY, like other serotoninergic 
drugs, i.e. LSD, may have a serotoninergic activity throught the 5HT2a receptor . 
This hypothesis is supported by the molecular structure of BZY, in which is 
presented the indole compound, tipical of the serotonine and other psychoactive 
molecules. Likewise, BZY share a common molecular structure with several CB1 
synthetic agonists (i.e. JWH series compounds), which proved to have 
hallucinogenic proprieties as well (Forrester, 2012; Harris and Brown, 2013).  
However, while there is no evidence for animal self-administration hallucinogenic 
substances, meaning that serotonin may not be reinforcing (Deneau et al., 1969; 
Yanagita, 1986), we showed that BZY is able to develop and mantain self-
administration behavior in rats. Therefore BZY may share a common mechanism 
with amphetamine derivatives rather than the serotoninergic hallucinogens. Indeed, 
numerous studies reported self-administration of MDMA in animals (Fantegrossi et 
al., 2002; Lamb et al., 1987; Schenk et al., 2003, 2007; Sannerud et al., 2006).  
 
In summary, our data demonstrate a BZY-induced long-term depression of PFc to 
NAcore synapses in mediating BZY self-administration behavior, thereby 
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supporting the postulated contribution of PFc neuroadaptations in addictive 
behavior. Specifically, we report that, BZY, like cannabinoids and amphetamine, 
presynaptically induced  long-term depression by the interaction with the 
endocannabinoid system. In future studies it will be interesting to dissect BZY 
molecular mechanism for a  better understanding of its abuse potential and its 
toxicological profile. In particular, a further aspect that needs to be investigated is 
the involvement of metabotropic glutamate receptor (mGlu) subtypes, widely 
expressed at the glutamatergic afferents to the Nac (Ohishi et al., 1993a; 
Shigemoto et al., 1993; Manzoni et al., 1997). In particular we will focus on the 
mGlu 2/3 in view of its key roles in controlling LTD in the hippocampus, amygdala, 
prefrontal cortex and dorsal striatum (Kahn et al., 2001; Kobayashi et al., 1996; 
Yokoi et al., 1996; Tzounopoulos et al., 1998; Huang et al., 1997, 1999; Lin et al., 
2000; Otani et al., 1999). 
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